Pharmaceuticals news and pharmaceuticals widget

Sunday, July 06, 2008 ( change date )

Beijing Genomics Institute signs global site license with CLC bio for Next Generation Sequencing software platform

Beijing Genomics Institute (BGI) has signed a global site license agreement for CLC bio's Next Generation Sequencing solution, CLC Genomics Workbench. The site license covers all researchers at all ...

bionity.com Sunday, July 06, 2008

Evotec's EVT 101 well tolerated in four week higher repeat dose safety study

Evotec AG announced top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active NR2B-subtype selective antagonist of NMDA receptors with potential in Alzheimer's disease, ...

bionity.com Sunday, July 06, 2008

Movetis' second most advanced product progresses to Phase IIb trial following positive results in cirrhotic ascites

Movetis NV, a European specialist pharmaceutical company, announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ...

bionity.com Sunday, July 06, 2008

Shire to add new orphan drug to its HGT portfolio

Shire Limited, the global specialty biopharmaceutical company, announced that Maia Elfte Vermögensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German indirect subsidiary of ...

bionity.com Sunday, July 06, 2008

Gastric Bypass Surgery May Play Role in Preventing Cancer

UNION, New Jersey, June 22, 2008 - After attending the American Society for Metabolic & Bariatric Surgery's Annual Meeting in Washington DC this past week, New Jersey Bariatric Center's Dr. Ajay Goyal... [WebWire - Sunday, July 06, 2008]

Webwire Sunday, July 06, 2008

Introgen cuts 29% of jobs as it moves to market cancer therapy

Introgen Therapeutics Inc. is reducing its development staff to focus on regulatory review and commercial activities. (INGN)

bizjournals Sunday, July 06, 2008